Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α) inhibitors are primarily reserved for moderate to severe disease that is refractory to conventional therapies or for the first-line treatment of very severe disease. Takeda’s CAM inhibitor, Entyvio, and Janssen’s IL-12 / IL-23 inhibitor, Stelara, are alternative options, especially for TNF-α-refractory patients. In addition, Pfizer’s JAK inhibitor, Xeljanz / Xeljanz XR, is the first oral agent approved (2018) to treat UC. These three newer drugs are not approved for pediatric UC, but, given the limited number of therapies available for pediatric patients who fail TNF-α inhibitors, physicians may turn to them as last-line options.


  • What percentage of pediatric UC patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric UC patients?
  • How have Entyvio, Stelara, and Xeljanz been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of pediatric UC patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Ulcerative Colitis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) – Pediatric

Author(s): Maria Genco, Ph.D

Maria Genco, Ph.D., is an analyst on the Immune and Inflammatory Disorders group at Decision Resources Group, primarily focusing on rheumatoid arthritis and axial spondyloarthritis. She has authored market research reports on the RA disease landscape and commercial outlook of drugs, unmet needs in RA, and market access and reimbursement for RA targeted therapies. Prior to joining Decision Resources, Dr. Genco received her M.S. and Ph.D. in neuroscience from Brandeis University and a B.A. in neuroscience from Wellesley College.

Related Reports

Ulcerative Colitis - Landscape & Forecast - Disease Landscape & Forecast

The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz / Xeljanz XR) for the moderate to severe...

View Details

Ulcerative Colitis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) Dashboard

Ulcerative colitis (UC) is a chronic inte...

View Details

Ulcerative Colitis - Unmet Need - Detailed, Expanded Analysis (US & EU)

The moderate to severe ulcerative colitis (UC) drug market still offers substantial opportunity for companies that can address the remaining unmet needs in t...

View Details